Funding Wizard

The District has developed this new pilot incentive program to target the installation of electric feed mixing equipment and further reduce diesel emissions from tractors and other mobile equipment and vehicles at Valley dairies and other confined animal feeding operations (CAFOs). The primary emission reductions from this program will be from the elimination of existing ag tractors that mix and deliver feed, the elimination or reduction in usage of on-road trucks used to deliver feed, and reduction in usage of any remaining off-road equipment used in the feeding process. Further emission reductions and cost-savings to Valley dairies and CAFO's will be achieved through increased efficiencies of the new systems that result in an overall reduction in feed mixing equipment usage. Due to the complexity of this program, it is strongly advised that interested applicants speak with program staff to ensure proper submittal of an application.

Do you live in an apartment or manufactured home? Do you own or operate a multifamily or manufactured housing community? If so, we may have ways to help reduce  your energy costs by participating in the new innovative Residential Zero Net Energy Transformation (RZNET) program. 

The Residential Zero Net Energy Transformation (RZNET) program will  assist SDG&E multifamily and manufactured housing customers with navigating their path to zero net energy. 

What is Zero Net Energy(ZNE)?  ZNE is the total amount of energy used by the building on an annual basis is equal to or less than the amount of renewable energy (energy created by sources that are naturally replenished, such as wind, rain, or solar) created on-site.

RZNET allows you to connect with an Energy Advisor that will help you make informed decisions about how to achieve your energy efficiency goals. 

RZNET program participants on the path to zero net energy, begin with the installation of no-cost measures and a complimentary ASHRAE Level 1 audit. Information on advanced energy efficiency, solar PV installations, and battery storage opportunities for multifamily and manufactured housing properties is also available.   

No- cost Measures may include:

• Low flow showerheads
• Low flow aerators
• Pipe  (near water heater)
• Auto-diverting tub spout
• ECM furnace motor replacement
• Air conditioning tune-up
• Efficient fan control
• Smart thermostat

The blood brain barrier (BBB) is a target of both the HIV virus and substances of abuse. It is a site of entry for HIV infected monocytes and macrophages that can traverse the BBB either paracellularly or transcellularly. HIV viral proteins can also attack astrocytes and tight junctions of BBB directly and compromise its integrity, resulting in the crossing of the virus, as well as abused substances, into the brain. Meanwhile, many substances of abuse cause BBB dysfunction. Because BBB integrity regulates both substances and virus levels in the brain, it is critical to establish the mechanisms by which HIV infection, in combination with substances of abuse, affect BBB function and integrity and their consequences. The purpose of this initiative is to support innovative research that elucidates the roles of HIV and addictive substances in the pathology of BBB. This FOA encourages studies to expand the current understanding of the basic molecular mechanisms underlying virus mobilization across BBB, and pathology of BBB in HIV infection and substance use disorders (SUD). In addition, studies are encouraged to develop and test novel BBB models to assess the delivery of pharmacological and immunotherapies to treat HIV infection and SUD, and to suppress HIV replication in CNS.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit R01 research projects that investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal the PAIRS program is to the development of radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.

Note: Each funding opportunity description is a synopsis of information in the Federal Register application notice. For specific information about eligibility, please see the official application notice. The official version of this document is the document published in the Federal Register. Free Internet access to the official edition of the Federal Register and the Code of Federal Regulations is available on GPO Access at: http://www.access.gpo.gov/nara/index.html. Please review the official application notice for pre-application and application requirements, application submission information, performance measures, priorities and program contact information. For the addresses for obtaining and submitting an application, please refer to our Revised Common Instructions for Applicants to Department of Education Discretionary Grant Programs, published in the Federal Register on December 27, 2021. Within IES, the National Center for Special Education Research (NCSER) supports research to expand knowledge and understanding of the needs of infants, toddlers, and youth with disabilities to improve the developmental, education, and transition outcomes of such individuals. Through NCSER, IES invests in Special Education Research and Development Centers (R&D Centers) that contribute to the body of special education knowledge in the United States by engaging in research, development, evaluation, and national leadership activities aimed at improving the education system and, ultimately, student achievement. Through this program, NCSER seeks to establish a new R&D Center on Supporting Students with Disabilities in Postsecondary Education. NCSER Competition The Special Education Research and Development Center Competition (ALN 84.324C). Under this competition, NCSER will consider only applications that address the following topic: · Research Center on Supporting Students with Disabilities in Postsecondary Education. Assistance Listing Number (ALN): 84.324C.

This funding opportunity announcement (FOA) invites applications for new ECHO Cohort Study Sites to extend and expand the capacity of the ECHO Cohort to further investigate the roles of a broad range of early exposures from society to biology, including the preconception period, on ECHOs five key child health outcome areaspre-, peri- and postnatal, upper and lower airways, obesity, neurodevelopment, and positive healthamong diverse populations. The objectives of this FOA are to solicit applications to 1) lead collaborative ECHO Cohort science, 2) recruit new pregnant participants from diverse populations, their resulting offspring, and, if available, the conceiving partner, 3) develop and implement the ECHO Cohort Preconception Pilot Study, and 4) implement the ECHO Cohort Data and Biospecimen Collection Protocol using the ECHO Cohort consortiums central data capture system, e.g., REDCap Central. This FOA does not support site-specific analyses and science. This new funding period will be 7 years in duration provided successful performance in the UG3 phase and the UH3 phase. This FOA runs in parallel with companion FOAs that solicit applications for Cohort Study Sites only for a limited competition of follow-up of existing ECHO Cohort participants (RFA XXXX), for ECHO Cohort Study Sites only for a limited competition of follow-up of existing ECHO Cohort participants AND of recruitment of new pregnant participants, their resulting offspring, and, if available, the conceiving partner (RFA ZZZZ), for an ECHO Coordinating Center (RFA NNNN), for an ECHO Data Analysis Center (RFA NNNN), for an ECHO Measurement Core (RFA NNNN), and for an ECHO Laboratory Core (RFA NNNN).

This Funding Opportunity Announcement (FOA) encourages UG3/UH3 phased cooperative research applications to accelerate implementation of effective non-opioid interventions for chronic pain management in rural and remote populations. Projects include pragmatic, implementation, or hybrid effectiveness-implementation trials to improve pain management and reduce the use of inappropriate opioid medications. Awards made under this FOA will initially support a milestone-driven, planning phase (UG3) of 1 to 2 years, with possible transition to an implementation phase (UH3) of up to 4 years duration (5 years total for the two phases). UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The overall goal of this initiative is to support the "real world" implementation of effective interventions to manage pain in rural and remote areas. Results from the trials supported by this funding opportunity announcement (FOA) should inform policy makers, payers, community stakeholders, as well as health care providers and patients in the primary care, emergency department, hospital, home health, or dental setting. This FOA requires that the investigators partner with one or more rural healthcare system(s) to plan and implement the intervention. During the planning phase, investigators must develop an additional one or more community-based partnership(s). Studies may propose to integrate multi-component, bundled, or multi-level interventions that have demonstrated efficacy.

Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the adoption of these emerging technologies by appropriate research communities.As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grants (T35) to eligible, domestic institutions to develop and/or enhance research training opportunities for predoctoral students interested in careers in biomedical, behavioral, or clinical research. Many NIH Institutes and Centers (ICs) use this NRSA program exclusively to support intensive, short-term research training experiences for health professional students (medical students, veterinary students, and/or students in other health-professional programs) during the summer. This program is also intended to encourage training of graduate students in the physical or quantitative sciences to pursue research careers by short-term exposure to, and involvement in, the health-related sciences. The training should be of sufficient depth to enable the trainees, upon completion of the program, to have a thorough exposure to the principles underlying the conduct of biomedical research. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.